Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-617 Treatment Pause vs Standard Treatment in mCRPC
NCT06200103Phase 2Suspended
- Sponsor
- Mayo Clinic
- Start
- May 2024
- Primary completion
- Dec 2029
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Mayo Clinic. Started May 2024; status: suspended.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06200103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06200103.